Immunowake closes $20M in pre-Series A
Shanghai, China - 15th May 2022. Immunowake has raised $20M in pre-series A financing. This funding round was led by Hyfinity Investments, followed by South China Venture, Lapam Capital, and HEDA Ventures.
Immunowake Announces Licensing Agreements with GenSci and GenScript
Birmingham, AL - 5th March 2020. Immunowake Inc. announced that it has entered into agreements with Genescience Pharmaceuticals Co., Ltd and Genscript Biotech Corp (HKG: 1548) in which Immunowake will obtain exclusive licenses to PD-L1 antibodies for the development of multi-target therapeutics. Terms of the agreement were not disclosed.
Immunowake raises $3M in Financing
Birmingham, AL - 22nd August 2019. Immunowake has raised $3M in financing, led by Changchun High-tech Industries Group Inc (SZSE: 000661). This investment will be used to accelerate the research, development, and commercialization of Immunowake’s portfolio.